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Abstract
 
The BCR-ABL1 kinase expressed in acute lymphoblastic leukemia (ALL) drives malignant
transformation of human pre–B cells. Comparing genome-wide gene expression profiles of
 
BCR
 
-
 
ABL1
 

 
 pre–B ALL and normal bone marrow pre–B cells by serial analysis of gene expression,
many genes involved in pre–B cell receptor signaling are silenced in the leukemia cells. Although
normal pre–B cells are selected for the expression of a functional pre–B cell receptor, 
 
BCR-
ABL1
 

 
 ALL cells mostly do not harbor a productively rearranged 
 
IGH
 
 allele. In these cases, we
identified traces of secondary V
 
H
 
 gene rearrangements, which may have rendered an initially
productive V
 
H
 
 region gene nonfunctional. Even 
 
BCR-ABL1
 

 
 ALL cells harboring a functional
V
 
H
 
 region gene are unresponsive to pre–B cell receptor engagement and exhibit autonomous
oscillatory Ca
 
2
 

 
 signaling activity. Conversely, leukemia subclones surviving inhibition of
BCR-ABL1 by STI571 restore responsiveness to antigen receptor engagement and differentiate
into immature B cells expressing immunoglobulin light chains. BCR-ABL1 kinase activity is
linked to defective pre–B cell receptor signaling and the expression of a truncated isoform of
the pre–B cell receptor–associated linker molecule 
 
SLP65
 
. Also in primary leukemia cells,
truncated 
 
SLP65
 
 is expressed before but not after treatment of the patients with STI571. We
conclude that inhibition of BCR-ABL1 reconstitutes selection for leukemia cells expressing a
functional (pre–) B cell receptor.
Key words: immunoglobulin • SLP65 • differentiation • STI571 • V(D)J recombination
 
Introduction
 
Several transcription factors, including 
 
PAX5
 
, 
 
E2A
 
, and
 
EBF
 
, guide commitment of hematopoietic stem cells to the
B cell lineage (1). Committed B cell precursors undergo a
sequence of Ig gene rearrangements defining distinct stages
of early B cell development (2). During their early devel-
opment within the bone marrow, B cell precursors have to
pass checkpoints, at which only cells carrying functional Ig
gene rearrangements are selected for further development
along the B cell lineage (3). For instance, the presence of a
productive 
 
IGH
 
 gene rearrangement is a prerequisite for
the expression of the Ig 
 

 
 heavy chain as a component of
the pre–B cell receptor on the surface of a pre–B cell (4). If
these cells initially fail to express a functional pre–B cell
receptor on their surface because of a nonproductive 
 
IGH
 
gene rearrangement on one allele, they can continue to
rearrange Ig V region genes on the second 
 
IGH
 
 allele or
undergo secondary V
 
H
 
 gene recombination on the nonpro-
ductively rearranged allele (5). Pre–B cells are destined to
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Abbreviations used in this paper:
 
 ALL, acute lymphoblastic leukemia; CMP,
common myeloid progenitor cell; cRSS, cryptic recombination signal
sequence; GCB, germinal center B cell; HSC, hematopoietic progenitor
cell; KDE, 
 

 
 deleting element; MBC, memory B cell; NBC, naive B cell;
SAGE, serial analysis of gene expression; TLP, T lymphoid precursor.
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die by apoptosis unless they are rescued by survival signals
through their pre–B cell receptor. The pre–B cell receptor
complex including the Ig 
 

 
 heavy chain, the surrogate light
chain composed of 
 

 
5 and VpreB, CD19, and the Ig
 

 
 and
Ig
 

 
 signal chains does not only convey survival signals but
also terminates the rearrangement process within the 
 
IGH
 
locus. A critical component in the pre–B cell receptor sig-
naling cascade is the adaptor molecule SLP65, which links
SYK to downstream effector pathways, including PLC
 

 
2,
BTK, and VAV (6). Although somatic 
 
SLP65
 
 deficiency is
a frequent aberration in pre–B acute lymphoblastic leuke-
mia (ALL) in humans (7), 
 
SLP65
 
	
 
/
 
	
 
 mutant mice exhibit a
differentiation block at the pre–B cell stage (8), and also
show autonomous proliferation, ongoing rearrangement of
 
IGH
 
 V region genes, and development of leukemia (9).
In most cases of ALL, pre–B cells represent the normal
counterpart of the malignant clone, which in many cases
carries specific oncogenic gene rearrangements defining
both biological and clinical subentities (10). Among these
translocation events, the t(9;22) (q34;q11) results in a fusion
of the 
 
BCR
 
 and 
 
ABL1
 
 genes (11), which codes for a potent
tyrosine kinase and represents the most frequent recurrent
genetic aberration leading to ALL in adults (12). Comparing
pre–B ALL carrying a 
 
BCR-ABL1
 
 gene rearrangement to
pre–B ALL harboring other translocations, recent studies
using the cDNA microarray technique identified differen-
tially expressed genes predicting a 
 
BCR-ABL1
 
 fusion. Aim-
 
ing at molecular classification of leukemia, these works
searched for differentially expressed genes discriminating be-
tween various subentities of ALL (13, 14). In an alternative
approach using the serial analysis of gene expression (SAGE)
technique, we compared genome-wide gene expression
profiles of normal hematopoietic bone marrow populations,
including pre–B cells, hematopoietic progenitor cells, my-
eloid progenitor cells, T lymphoid precursors (TLPs), and
BCR-ABL1
 

 
 pre–B ALL, which are thought to represent
the malignant outgrowth of pre–B cells (12). The leukemia
cells were also compared with mature B cell populations,
including naive B cells (NBCs), germinal center B cells
(GCBs), memory B cells (MBCs), and plasma cells (PCs).
These comparisons were meant to (a) identify novel target
genes of BCR-ABL1–mediated transformation, and (b) to
elucidate how the oncogenic BCR-ABL1 kinase may inter-
fere with normal pre–B cell receptor signaling.
 
Materials and Methods
 
Patient Samples and Cell Purification.
 
In total, 19 cases of 
 
BCR-
ABL1
 

 
 pre–B ALL were studied. For cases I–IX (Table I), 
 
BCR-
ABL1
 

 
 pre–B ALL cells obtained from bone marrow samples of
untreated patients had a purity of 
 


 
95% as assessed by bone mar-
row morphology. Cases X–XII (Table I) correspond to 
 
BCR-
ABL1
 

 
 pre–B ALL cell lines, termed SUP-B15, BV173, and
NALM1 (DSMZ), respectively. Purification of ALL cells from
 
Table I.
 
Clinical Data on BCR-ABL1
 

 
 Pre–B ALL Cases Studied
 
Case Age Sex
 
BCR-ABL1
 
 fusion Clinical course
I 34 m p190 complete remission after BMT
II 32 m p190 died after BMT
III 76 m p190 chemotherapy, died 3 wk after onset of therapy
IV 30 m p190 complete remission after BMT, currently GVHD
V 66 f p190 complete remission after chemotherapy
VI 10 f p190 died after BMT
VII 56 m p190 chemotherapy, currently in remission
VIII 10 f p190 died after BMT, GVHD
IX 16 m p210 complete remission after BMT
X 9 m p190 died after relapse (SUP-B15 cell line)
XI 45 m p210 died after relapse (BV173 cell line)
XII 3 f p210 died after relapse (NALM1 cell line)
XIII 39 m p210 relapse after STI571 treatment
XIV 54 f p190 relapse after STI571 treatment
XV 61 f p190 relapse after STI571 treatment
XVI 51 m p190 relapse after STI571 treatment
XVII N.K. N.K. p190 relapse after STI571 treatment
XVIII 65 m p190 relapse after STI571 treatment
XIX 47 f p190 relapse after STI571 treatment
Sequencing analysis for 
 
IGH
 
 alleles, cases I–XII. SAGE analysis, cases II and IX. Comparison of 
 
SLP65
 
 isoform expression before and after STI571
treatment, cases XIII–XIX.
m, male. f, female. BMT, bone marrow transplantation. N.K., not known. GVHD, graft versus host disease.
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cases XIII–XIX (Table I) was described previously (15). In these
cases, 
 
SLP65
 
 isoform expression before and after treatment with
the BCR-ABL1 inhibitor STI571 and expression of CD10, CD19,
and CD34 was studied (Fig. 4; Table I, cases XIII–XIX). For nine
primary cases (including two cases analyzed by SAGE: II and IX)
and three cell lines, the configuration of 
 
IGH
 
 loci was examined
(Table II, cases I–XII). For all cases, breakpoints within the major
or minor breakpoint cluster region of the 
 
BCR
 
 gene, leading to
p210 and p190 fusion molecules, respectively, were detected by
PCR using primers and PCR conditions as described previously
(16). Clinical data for all 19 cases are given in Table I. Normal he-
matopoietic cell populations, including CD34
 

 
 CD38
 
low
 
 CD133
 

 
Lin
 
	
 
 hematopoietic progenitor cells (HSCs), CD15
 

 
 common
myeloid progenitor cells (CMPs), CD7
 

 
 CD10
 

 
 T lymphoid pre-
cursors (TLPs), CD19
 

 
 VpreB
 
	
 
 Ig
 

 
 chain
 
	
 
 pro–B cells (no SAGE
profile available), and CD10
 

 
 CD19
 

 
 Ig
 

 
 chain
 

 
 pre–B cells were
enriched from human bone marrow by depletion of unwanted
cells and enrichment of the populations of interest using immuno-
magnetic beads and cell sorting. Mature B cell populations, includ-
ing CD19
 

 
 CD27
 
	
 
 
 
NBCs, CD19
 

 
 CD27
 

 
 MBCs, and CD19
 

 
CD138
 

 
 PCs were from pooled peripheral blood samples of 12
healthy donors. CD20
 

 
 CD77
 

 
 GCBs were isolated from human
tonsillectomy resectates. HSCs, CMPs, TLPs, pre–B cells, NBCs,
MBCs, and PCs were subjected to SAGE analysis as described pre-
viously (17–19). SAGE data on GBCs were provided by I. Schwer-
ing and R. Küppers (University of Cologne, Cologne, Germany
and University of Essen, Essen, Germany, respectively).
 
SAGE Analysis.
 
cDNA synthesis, SAGE analysis, and clon-
ing and sequencing of SAGE concatemers was performed as
described previously (17–19). The UniGene reference database
(March 2001) was obtained at http://www.sagenet.org/
SAGEDatabases/unigene.htm. A total of 592,000 SAGE tags
were collected for 10 SAGE profiles. 106,000 tags were analyzed
for the HSC library, 99,000 for CMPs, 110,000 for pre–B cells,
96,500 for T lymphoid precursors, and each of 
 

 
30,000 tags for
two cases of bone marrow–derived pre–B ALL carrying a 
 
BCR-
ABL1
 
 gene rearrangement, NBCs, GBCs, MBCs, and PCs. All
SAGE libraries were normalized to 100,000 tags. SAGE data
were graphically visualized using the Cluster and Treeview soft-
ware (http://rana.lbl.gov) and sorted according to the ratio be-
tween SAGE-tag counts in pre–B cells and in 
 
BCR-ABL1
 

 
 ALL
cases. In a comprehensive search for pre–B cell receptor compo-
nents and pre–B cell receptor–related signaling molecules in
PubMed, UniGene (http://www.ncbi.nlm.nih.gov/UniGene), and
OMIM (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db
 

 
OMIM), we identified 54 genes in at least one of the SAGE-
libraries analyzed, for which a role in the assembly or regulation
of the pre–B cell receptor was shown.
 
Semi-quantitative RT-PCR Analysis and Verification of Quantita-
tive Accuracy of SAGE Data.
 
To corroborate quantitative differ-
ences in gene expression as determined by SAGE, semi-quantita-
tive RT-PCR analysis was performed for a set of 45 selected
genes differentially expressed between HSCs and pre–B cells and
41 genes differentially expressed between NBCs and MBCs as
described previously (17, 18).
To verify differential gene expression observed by SAGE-anal-
ysis of pre–B cells and the 
 
BCR-ABL1
 
 
 
pre–B ALL cell line
SUP-B15, we performed semi-quantitative RT-PCR using the
following primers: 
 
GAPDH
 
 (for standardization), 5
 

 
-TTAG-
CACCCCTGGCCAAG-3
 

 
 and 5
 

 
-CTTACTCCTTGGAG-
GCCATG-3
 

 
; 
 
AML1
 
, 5
 

 
-AATGATGAAAACTACTCGGCT-
3
 

 
 and 5
 

 
-TTGGTCTGATCATCTAGTTTC-3
 

 
; 
 
GATA1
 
,
5
 

 
-AGTCTTTCAGGTGTACCCAT-3
 

 
 and 5
 

 
-AAAGAAGG-
 
TACTGGAAAAGTC-3
 

 
; 
 
EBF
 
, 5
 

 
-AAGGAAAAAGAAGC-
CAACAG-3
 

 
 and 5
 
-GGACAAACATGTTATCAGGA-3; E2A,
5-CTGAAAGCAAGCAACAAAAC-3 and 5-CACGGGG-
TCTTTTTAATACA-3; PAX5, 5-CCATGTAAATACCTT-
CTTGC-3 and 5-ATTCTGCTTCGGAAAAGTAG-3; OCT2,
5-CAAAATAAGACCTCCCCATT-3 and 5-TGAGGTAG-
CTGGAATAGATT-3; OBF1, 5-GGCTTCAAAGAGAAA-
AGGCA-3 and 5-TCTGTCGTGACATTGGTGAT-3; and
IRF4, 5-CAAGAGCAATGACTTTGAGG-3 and 5-TGG-
GACATTGGTACGGGAT-3. The same primer sets were also
used for RT-PCR analysis of STI571-treated SUP-B15 ALL
cells after MACS enrichment of  and 	 subclones.
In addition, quantitative differences between the SAGE librar-
ies for pre–B cells and BCR-ABL1 pre–B ALL cases were veri-
fied at the protein level for 10 surface molecules by flow cytome-
try using antibodies against CD19, IL7R, CD10, CD38, CD40,
CD150/SLAM, CD72, VpreB, Ig, and CD34 (BD Biosciences;
unpublished data).
Sequence Analysis of IGH Loci. To characterize the configura-
tion of the IGH loci in nine primary BCR-ABL1 pre–B ALL
cases (Table II, cases I–IX) and three cell lines (SUP-B15,
BV173, and NALM1; Table II, cases X–XII), three primer sets
were used to amplify germline configuration, D-J and V-DJ
gene rearrangements from both alleles of the IGH locus. Clonal
VH gene rearrangements were amplified in a single round of
PCR amplification using 35 PCR cycles at a detection limit of
104 clonal cells in 5  106 total cells. PCR primers and condi-
tions were used as described previously (20) and amplification
products were directly sequenced and aligned according to Mat-
suda et al. (21) using the IMGT software at http://www.
dnaplot.de/input/human_v.html. To identify footprints from
formerly rearranged VH gene segments within potential second-
ary VDJ rearrangements, a list of VH and DH germline gene seg-
ments was obtained at http://imgt.cines.fr and the cryptic re-
combination signal sequence (cRSS) was identified as described
previously (22).
Measurement of pre–B Cell Receptor Responsiveness. Primary
human CD19 bone marrow mononuclear cells were enriched
from bone marrow samples of four healthy donors using immu-
nomagnetic MACS beads as described previously (17). SUP-B15,
BV173, and NALM1 pre–B ALL cells (DMSZ) carrying a BCR-
ABL1 gene rearrangement (Table II, cases X–XII) were cultured
with 20% fetal calf serum in RPMI 1640 medium in the presence
or absence of 10 M STI571 (Novartis) for the times indicated.
Among STI571-treated leukemia cells, Ig and Ig	 cells were
separated using a nonstimulating, biotin-conjugated anti- anti-
body (BD Biosciences) together with streptavidin microbeads
(Miltenyi Biotech). After MACS enrichment or preincubation,
cells were washed and stained with Fluo-3 dye (Calbiochem) for
30 min. Changes of cytosolic Ca2 were measured by laser scans
using confocal microscopy (18, 19). After 10–30 s of measure-
ment, antibodies against human  chains (Jackson ImmunoRe-
search Laboratories), VpreB (BD Biosciences), or Ig- together
with Ig-light chains (BD Biosciences) were added to CD19
bone marrow mononuclear cells or preincubated pre–B ALL cells
(in the presence or absence of STI571; cases X–XII). Cytosolic
Ca2 concentrations were determined as described previously
(18). As a negative control, cells were also treated with an anti-
body against CD3 (BD Biosciences), which induces Ca2 mobili-
zation in T but not B lineage cells.
Flow Cytometry. Surface expression of VpreB surrogate or
Ig- or Ig-light chains, Ig -chains and CD19 on BV173,
NALM1, and SUP-B15 pre–B ALL cells in the presence or ab-
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sence of 10 M STI571 was monitored using antibodies against
VpreB, Ig- or Ig-light chains, the Ig  heavy chain and CD19
(BD Biosciences) after the incubation times indicated. Apoptotic
or dead cells were identified by staining with anti–Annexin V an-
tibodies and propidium iodide (BD Biosciences).
RT-PCR Analysis of SLP65 Isoform Expression. cDNA
amounts were normalized by OD measurements and amplifica-
tion of a specific fragment of the GAPDH gene using 5-TTAG-
CACCCCTGGCCAAGG-3 as forward and 5-CTTACTC-
CTTGGAGGCCATG-3 as reverse primers. For amplification
of SLP65 isoforms, forward primers specific for exon I, 5-TG-
GACAGTTATTCGTGTCTCTT-3, and additional exon IIIb,
5-AGAGTGTGTTGACCTTGGTG-3, were used together
with a reverse primer specific for additional exon IIIb, 5-TTG-
GCTTAGAGGGTTTTGG-3, and exon VII, 5-GTGAACT-
GCTTTCTGTGGGA-3, as described previously (8). For am-
plification of another additional exon IIIa, the forward primer,
5-TTTAATCTCTCCTGGAATGCAG-3 was used. How-
ever, a splice variant including exon IIIa (8) could not be ampli-
fied with this primer (unpublished data). cDNAs derived from
human pre–B cells, BCR-ABL1 pre–B ALL cells in the pres-
ence or absence of STI571 and MACS-sorted -chain and
-chain	 BCR-ABL1 pre–B ALL cells after treatment with 10
M STI571, were used as RT-PCR templates.
Results and Discussion
Pre–B Cell Receptor-associated Signaling Molecules Are Silenced
in BCR-ABL1 pre–B ALL Cells. To identify target genes
of the oncogenic BCR-ABL1 kinase, we compared ge-
nome-wide gene expression profiles of two cases of BCR-
ABL1 pre–B ALL and normal hematopoietic populations
using the SAGE technique. For the SAGE analysis of nor-
mal hematopoietic populations, a total of 592,000 SAGE
tags have been collected, including CD10 CD19 human
bone marrow pre–B cells as the normal precursors of pre–B
ALL, CD7 CD10 TLPs, CD15 CMPs, CD34
CD38low HSCs, CD19 CD27	 NBCs, CD20 CD77
GCBs, and CD19 CD27 MBCs, and CD19 CD138
PCs (Fig. 1). Comparing the gene expression pattern in
BCR-ABL1 pre–B ALL and normal human pre–B cells,
many genes conferring B cell lineage commitment and sig-
nal transduction through the pre–B cell receptor were tran-
scriptionally silenced in the leukemic cells (Figs. 1 and 2).
Loss of pre–B cell receptor–related molecules in the pre–B
ALL cells involves nuclear transcription factors (Fig. 2,
OBF1, PAX5, E2A, OCT2, EBF, and IRF4), cytoplasmic
kinases and linker molecules (Fig. 1, LYN, BLK, BTK,
Figure 1. Expression of pre–B cell receptor–related molecules in BCR-ABL1 pre–B ALL cells. Using the SAGE method, 10 genome-wide gene
expression profiles have been generated for CD34 CD38low hematopoietic progenitor cells (HSCs), CD15 common myeloid progenitor cells (CMPs),
CD7 CD10 T cell lineage precursors (TLPs), CD10 CD19 Ig pre–B cells (pre-Bs), CD19 CD27	 naive B cells (NBCs), CD20 CD77
germinal center B cells (GCBs), CD19 CD27 memory B cells (MBCs), and CD19 CD138 plasma cells (PCs), and compared with two cases of pre–B
ALL-carrying a BCR-ABL1 gene rearrangement (ALL, cases II and IX). SAGE-tag counts are given as numbers and depicted in colors, with red indicating
high and green indicating low levels or no expression. SAGE data were sorted according to the ratio of SAGE-tag counts for pre–B cells and SAGE-tag
counts in BCR-ABL1 ALL cases. In addition to gene names, annotations of proposed gene functions (including a reference) are given.
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BRAG, SLP65, SYK, BAP37, IgBP1, BRDG1, PLC2,
VAV1-3, HPK1, LCK, FYN, BAM32, AKT, SHC1, SAP,
p62DOK, CIN85, NIK, and IKK), and membrane-associ-
ated receptor molecules (Fig. 1, CD19, IGH, VpreB, Ig,
and Ig). Conversely, transcription factors related to primi-
tive hematopoiesis, including AML1 and GATA1, are up-
regulated in the leukemia cells as compared with their nor-
mal counterpart (Fig. 2). Also, signaling molecules related to
NF-B, JAK-STAT, GAB2, and GRB2 pathways are ex-
pressed in the leukemia cells at similar or higher levels than
in pre–B cells (Fig. 1, bottom). However, NF-B activation
(23) and GAB2/GRB2 phosphorylation (24, 25), together
with expression of JAK and STAT proteins (26), reflect on-
cogenic BCR-ABL1 kinase activity or requirements for
transformation by BCR-ABL1 rather than pre–B cell recep-
tor signaling in the leukemia cells.
BCR-ABL1 pre–B ALL Cells Carry Nonproductive VH
Gene Rearrangements in Most Cases. These findings suggest
that BCR-ABL1 pre–B ALL cells as opposed to normal
bone marrow pre–B cells do not express an active pre–B cell
receptor. Therefore, we investigated whether the genomic
configuration of the IGH loci in BCR-ABL1 pre–B ALL
cells is compatible with the expression of a functional pre–B
cell receptor. Only 3 out of 12 BCR-ABL1 pre–B ALL
cases harbored a potentially functional IGH gene rearrange-
ment (Table II). In the remaining nine cases, the coding ca-
pacity of IGH alleles was compromised by loss of the reading
frame or generation of stop codons within the junction be-
tween V, D, and J segments during the rearrangement pro-
cess. To formally exclude that in these cases a productive
VH-DHJH rearrangement on the second allele might have
been missed during the PCR amplification, we also ampli-
fied the second IGH allele using primers specific for IGH
germline configuration or DH-JH rearrangements (Table II).
In one case (Table II, case IV), two IGH VDJ rearrange-
ments were amplified, both of which were nonfunctional.
Hence, the majority of pre–B ALL clones carrying the
oncogenic BCR-ABL1 gene rearrangement can survive
and even clonally expand in the absence of pre–B cell re-
ceptor survival signals. We conclude that BCR-ABL1 leu-
kemia cells can bypass selection for the expression of a pre–B
cell receptor.
However, because clonal VH gene rearrangements were
amplified in a single round of PCR amplification at a rela-
tively low sensitivity (detection limit of 104 clonal cells in
5  106 total cells), we cannot exclude that small subclones
carrying a productive IGH allele were among the leukemia
cells. Of note, the two leukemia cases analyzed by SAGE
also differed with respect to the coding capacity of their
IGH alleles. However, irrespective of whether the leuke-
mia cells harbored a potentially productive IGH allele or
not, mRNA expression of pre–B cell receptor–related sig-
naling molecules was invariably down-regulated or missing
in both cases (Fig. 1).
Inhibition of BCR-ABL1 Kinase Activity Reconstitutes Selec-
tion of pre–B ALL Cells Expressing Ig -chains at High Levels.
To determine whether the BCR-ABL1 kinase has an effect
on the expression of the pre–B cell receptor, we measured
expression levels of surface Ig  heavy chain on three
BCR-ABL1 pre–B ALL cell lines (SUP-B15, BV173, and
NALM1) in the presence and absence of STI571, a specific
inhibitor of BCR-ABL1 kinase activity. CD19 bone mar-
row B lineage cells exhibit surface Ig  heavy chain expres-
sion at variable levels (Fig. 3 A). In contrast, Ig  heavy
chain protein was detectable only at very low levels on the
surface of SUP-B15 cells (Fig. 3 B) and NALM1 cells (not
depicted). On BV173 cells, Ig  heavy chains were de-
tected neither on the cell membrane nor in the cytoplasm
(not depicted), which is consistent with the absence of a
productive IGH allele in these cells (Table II, case XI).
However, after 19 h of STI571 treatment, a small subset of
3% of the leukemia cells expressed surface Ig  heavy
chain at high levels (Fig. 3 C). Only few ALL cells survived
continued STI571 treatment, which further increased the
fraction of Ig high cells to 23% after 4 d (Fig. 3 F) and 48%
after 6 d (Fig. 3 D). In STI571-treated leukemia cells, ex-
Figure 2. Inhibition of BCR-ABL1 in pre–B ALL
cells can restore expression of B cell–specific transcription
factors. SAGE-tag counts of hematopoietic stem cell–
related transcription factors AML1 and GATA1 and B
cell–specific transcription factors E2A, EBF, OBF1,
OCT2, IRF4, and PAX5 are compared between normal
pre–B cells and two cases of BCR-ABL1 pre–B ALL
(cases II and IX). Differential expression of these tran-
scription factors in pre–B cells as compared with leukemia
cells was verified by semi-quantitative RT-PCR using
cDNAs from normal pre–B cells and BCR-ABL1
SUP-B15 cells. Inhibition of BCR-ABL1 by STI571
could restore a pre–B cell–like expression pattern of
these transcription factors in Ig but not in Ig	
leukemia cells. Ig and Ig	 leukemia cells were
separated by MACS.
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pression of Ig  heavy chain surface correlated with viabil-
ity of the cells (i.e., lack of both annexin V membrane
expression and uptake of propidium iodide; Fig. 3 F).
Conversely, almost no Ig  heavy chain protein could be
detected on the surface of cells undergoing apoptosis in-
duced by STI571 (Fig. 3 F). During 6 d of STI571 treat-
ment, 
95% of all leukemia cells died by apoptosis. Thus,
the relative gain of Ig high cells can be fully attributed to
selective deletion of Ig 	 leukemia cells. We conclude
that ablation of BCR-ABL1 kinase activity by STI571 in-
duces selection of leukemia subclones expressing high lev-
els of -chains on their surface.
In STI571-treated patients, expression of -chains on
few leukemia subclones may confer a survival advantage
and, hence, represent an escape mechanism through which
some leukemic cells can temporarily evade STI571-
induced apoptosis. In the absence of BCR-ABL1 kinase
activity, the malignant cells would undergo apoptosis unless
they successfully reactivate other survival signals by default
(e.g., through the pre–B cell receptor).
Table II. Sequence Analysis of IGH Alleles in BCR-ABL1 Pre–B ALL Cases
Case Allele Configuration of IGH loci Coding capacity
Indication for secondary VH gene 
rearrangement
I 1 VH4.34-DH6.13-JH5 	 out of frame  (previously rearranged: VH1.8)
2 DH5-JH
II 1 VH4.61-DH2.2-JH4 	 out of frame; two stop codons in junction  (previously rearranged: VH1.58)
2 DH2.4-JH4
III 1 VH3.33-DH3.22-JH4 	 out of frame 	
2 DH7.27-JH; germline
IV 1 VH5.51-DH3.22-JH4 	 in frame; stop codon in junction 	
2 VH5.51-DH6.19-JH3 	 out of frame 	
V 1 VH5.51-DH1.26-JH1 	 in frame; stop codon in junction  (previously rearranged: VH2.5)
2 DH7.27-JH; germline
VI 1 VH3.30-DH3.22-JH3 	 out of frame  (previously rearranged: VH1.2)
2 DH5-JH
VII 1 VH1.46-DH6.13-JH4 	 out of frame  (previously rearranged: VH2.5)
2 DH5-JH
VIII 1 VH2.5-DH3.22-JH4 	 in frame; two stop codons in junction  (previously rearranged: VH2.70)
2 DH7.27-JH; germline
IX 1 VH1.46-DH3.10-JH5  in frame  (previously rearranged: VH1.24)
2 DH3.9-JH6
Xa 1 VH3.53-DH2.8-JH6  in frame  (previously rearranged: VH3.38)
2 ND
XIa 1 VH3.48-DH2.15-JH3 	 out of frame, stop codon in junction   (previously rearranged: VH3.38)
2 DH2-JH
XIIa 1 VH3.9-DH2.21-JH3  in frame 	
2 DH4-JH
aCases X–XII correspond to BCR-ABL1 pre–B ALL cell lines SUP-B15, BV173, and NALM1, respectively.
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After extended STI571 treatment, Ig high cells were not
only seen in SUP-B15 cells and NALM1 cells, which both
carry a functional IGH allele (Table II, cases X and XII).
Unexpectedly, they were also seen in BV173 cells, from
which we amplified two nonproductive IGH alleles that
gave rise to Ig high cells after prolonged exposure to
STI571. This could be explained by selective outgrowth of
few Ig high subclones of the BV173 cell line that already
existed before STI571 treatment (e.g., as a result of sponta-
neous secondary IGH gene rearrangement). Alternatively,
secondary IGH gene rearrangements might be induced by
STI571-mediated inhibition of BCR-ABL1. Therefore,
remedy of compromised coding capacity for a functional
pre–B cell receptor by BCR-ABL1-inhibition in the case
of BV173 cells exemplifies that survival signals through the
pre–B cell receptor would indeed allow leukemia cells to
temporarily evade STI571-mediated apoptosis.
BCR-ABL1 Kinase Activity Overrides pre–B Cell Receptor
Signaling in Leukemia Cells. To elucidate whether the
BCR-ABL1 kinase activity in leukemic pre–B cells cannot
only bypass selection for but also interfere with pre–B cell
receptor signaling, we compared antigen receptor respon-
siveness in human bone marrow pre–B cells (VpreB) and
immature B cells (Ig or Ig) and three BCR-ABL1
leukemia cell lines. Two out of the three cell lines (SUP-
Figure 3. Inhibition of BCR-ABL1 induces selection for Ig high leu-
kemia cells. Normal bone marrow mononuclear cells (MNCs) include B
lineage cells expressing Ig  heavy chains at variable levels, depending on
their differentiation stage as pro–B cells (Ig	), pre–B cells (Iglow), or
immature B cells (A, Ighigh). BCR-ABL1 SUP-B15 (B–F), BV173 (not
depicted), and NALM1 (not depicted) pre–B ALL cells were incubated in
the absence (B and E) or presence of 10 mol/l STI571 (C, D, and F) for
19 h (B and C), 2 (E and F) or 6 d (D) and measured for surface expression of
CD19 (A–D), Annexin V (E and F), and Ig  chains (A–F). Comparing
BCR-ABL1 SUP-B15 pre–B ALL cells to BV173 and NALM1 cells,
similar results were obtained (not depicted).
Figure 4. Inhibition of BCR-ABL1 in pre–B ALL cells results in selection
for subclones differentiating to immature B cells with preferential expression
of Ig  light chains. BCR-ABL1 SUP-B15, BV173, and NALM1 pre–B
ALL cells were cultured in the presence or absence of 10 mol/l STI571
for 2 d and surviving cells were analyzed for surface expression of Ig 
heavy chains, Vpre B surrogate light chains (top), Ig  light chains (middle),
and Ig  light chains (bottom). Inhibition of BCR-ABL1 by STI571 results
in preferential outgrowth of Ighigh cells, which down-regulate VpreB as
compared with Iglow cells and express conventional, predominantly 
light chains.
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B15 and NALM1; Table II, cases X and XII) indeed carry a
productive IGH allele and express surface Ig  heavy chain
at low levels together with VpreB (Fig. 4). To this end, we
measured Ca2 release in response to antigen receptor en-
gagement by anti-VpreB, anti-, anti-, and anti- anti-
bodies in normal pre–B and immature B cells and BCR-
ABL1 leukemia cells at the single cell level. Pre–B cells
and immature B cells showed the typical increase of cyto-
plasmic Ca2 reaching a plateau 1 min after pre–B cell
receptor cross-linking (Fig. 5 A). Comparing engagement
of pre–B cell receptors by anti-VpreB and cross-linking of
B cell receptors by anti- or anti-, the Ca2 signal initi-
ated by the pre–B cell receptor had a lower amplitude and
was slightly delayed (Fig. 5 A). In contrast, BCR-ABL1
SUP-B15 leukemia cells did not respond to anti–Ig  trig-
ger at all, even if fivefold-higher antibody concentrations
were used. Instead, the leukemia cells displayed a peculiar
autonomous oscillatory Ca2 signal activity (Fig. 5 B). Au-
tonomous Ca2 oscillations were not only seen in SUP-
B15 cells (Fig. 5 B) but also in BCR-ABL1 BV173 and
NALM1 leukemia cells (not depicted). To test whether au-
tonomous undulatory Ca2 signals are causally linked to
BCR-ABL1 kinase activity, we treated BCR-ABL1 SUP-
B15, BV173, and NALM1 cells with STI571. In the pres-
ence of STI571, the leukemia cells did not exhibit any au-
tonomous Ca2 signal activity. Instead, antigen receptor
responsiveness was partially restored in STI571-treated leu-
kemia cells. Upon pre–B or B cell receptor engagement by
anti- chain antibodies, some of the STI571-treated leuke-
mia cells responded by release of Ca2 from cytoplasmic
stores, whereas many other leukemia cells did not respond
to antigen receptor cross-linking (unpublished data).
To determine whether regained responsiveness of pre–B
cell receptors was restricted to differentiating Ig high cells
among the STI571-treated leukemia cells, Ig high and Ig
	 cells were separated by MACS after prolonged STI571
treatment. Although 48 out of 56 Ig high STI571-treated
cells responded by an oscillatory Ca2 signal, all 45 Ig 	
STI571-treated cells remained silent upon pre–B cell re-
ceptor engagement (Fig. 5 C).
We conclude that the BCR-ABL1 kinase establishes an
unusual autonomous signaling activity that overrides signal
transduction initiated by the pre–B cell receptor. Although
the kinetics of the Ca2 signal in STI571-treated leukemia
cells still clearly differs from the signaling pattern in normal
pre–B and immature B cells, inhibition of BCR-ABL1 ki-
nase activity restores responsiveness of the pre–B cell re-
ceptor in these leukemia cells.
BCR-ABL1 Leukemia Cells Surviving STI571 Treatment
Differentiate into Immature B Cells. Assuming a pre–B cell
origin of the three BCR-ABL1 leukemia cell lines ana-
lyzed, Ig  heavy chains on the surface of leukemia cells
surviving extended STI571 treatment were expressed at
surprisingly high levels (Fig. 3, D and E), which are charac-
teristic for  chain expression in the context of a B cell re-
ceptor rather than a pre–B cell receptor (12). Therefore,
we tested whether cells surviving prolonged STI571 treat-
ment were in fact differentiating into immature B cells,
which express high levels of surface -chain as part of a B
cell receptor. As shown in Fig. 4, Ig high leukemia cells
down-regulated VpreB as compared with Ig low cells (Fig.
4, top). Indeed, surrogate light chains on Ig high leukemia
Figure 5. Inhibition of BCR-ABL1 restores (pre) B cell receptor respon-
siveness in pre–B ALL cells. CD19 B lineage cells were purified from
bone marrow mononuclear cells using immunomagnetic beads. Release
of Ca2 from cytoplasmic stores in these cells in response to pre–B or B
cell receptor engagement by anti-VpreB or a mixture of anti- and anti-
chain antibodies (arrow) was measured using a laser scanning microscope
(A). Untreated BCR-ABL1 SUP-B15 (B), BV173, and NALM1 (not
depicted) pre–B ALL cells and BCR-ABL1 pre–B ALL cells incubated
with 10 mol/l STI571 for 24 h (C) were stimulated using an anti-
chain antibody, which can cross-link both pre–B and B cell receptors.
Among STI571-treated leukemia cells, Ig cells were separated from
Ig	 cells and analyzed independently (C). In B, fivefold higher concen-
trations of the anti- antibody than in A and C were used. The data
shown here refer to SUP-B15 cells. Analyzing BV173 and NALM1 cells,
similar results were obtained (not depicted).
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cells were replaced with conventional light chains (Fig. 4,
middle and bottom). We conclude that the three BCR-
ABL1 leukemia cell lines treated with STI571 exhibit
preferential outgrowth of subclones differentiating into im-
mature B cells. These findings are in agreement with a re-
cent paper on the effect of STI571 on v-abl–mediated dif-
ferentiation arrest in murine pre–B cells (27). However, in
the three BCR-ABL1 leukemia cell lines tested, the pat-
tern of light chain expression was heavily biased in favor of
-light chains (Fig. 4, bottom) and only few -expressing
cells could be detected (Fig. 4, middle), whereas Ig cells
in control stainings can easily be identified by the antibody
we used (not depicted).
Extensive -deleting Element (KDE) Rearrangement Results
in Preferential -light Chain Expression on STI571-surviving
Leukemia Cells. Searching for a potential explanation for
predominant -light chain expression on differentiating
leukemia cells surviving STI571 treatment, we investigated
whether rearrangement of the so-called KDE may contrib-
ute to reduced  light chain usage in STI571-treated leuke-
mia cells. KDE rearrangement may lead to inactivation of
productively recombined V-J joints and, hence, repre-
sents another level at which Ig light chain expression can
be regulated (28).
We amplified specific DNA fragments for KDE-germline
configuration, KDE rearrangement to an RSS within the J
intron, and KDE rearrangement to RSS sites flanking V
gene segments from three BCR-ABL1 leukemia cells in
the absence or presence of STI571. Although KDE was
found in germline configuration in untreated leukemia cells,
STI571-mediated inhibition of BCR-ABL1 was associated
with rearrangement of KDE to J intron RSS sites and, to a
lesser extent, to V RSS sites (not depicted). Thus, predom-
inant expression of  light chains is consistent with extensive
KDE rearrangement observed in our studies. In the absence
of BCR-ABL1 kinase activity, differentiating leukemia cells
seem to undergo multiple rounds of rearrangement targeting
both  and  light chain loci, which ultimately leads to pref-
erential  light chain expression due to KDE-mediated dele-
tion of potentially productive V-J joints.
Ig high Leukemia Cells Surviving STI571 Treatment Restore
Expression of B Cell–specific Transcription Factors. Propen-
sity of STI571-treated leukemia cells to differentiate into
light chain–expressing immature B cells suggests that these
cells exhibit a more mature phenotype as compared with
untreated leukemia cells. Therefore, we tested whether
STI571-treated differentiating leukemia cells can restore ex-
pression of B cell–specific transcription factors, which were
down-regulated in the untreated leukemia cells as compared
with normal pre–B cells (Fig. 2, SAGE data). BCR-ABL1
SUP-B15 pre–B ALL cells were cultured either in the pres-
ence or absence of STI571. Among STI571-treated leuke-
mia cells, Ig high and Ig 	 cells were separated by MACS
using immunomagnetic beads. From normal pre–B cells,
untreated ALL cells, STI571-treated Ig high cells, and
STI571-treated Ig 	 cells, cDNAs were synthesized
and subjected to semi-quantitative RT-PCR analysis for
mRNA levels of B cell–specific transcription factors (E2A,
EBF, OBF1, OCT2, IRF4, and PAX5) and the stem cell–
related transcription factors AML1 and GATA1 (Fig. 2).
The expression patterns of these transcription factors in
STI571-treated differentiating Ig high and normal pre–B
cells were similar, indicating that STI571-treated Ig high
leukemia cells indeed reversed the dedifferentiated stem
cell–like phenotype seen in untreated leukemia cells and
STI571-treated Ig 	 leukemia cells (Fig. 2).
Ablation of BCR-ABL1 Kinase Activity Corrects Expression
of Truncated SLP65 in pre–B ALL Cells from STI571-treated
Patients. An earlier work demonstrated that in the hu-
man, functional SLP65 is required for the expression of a
Figure 6. Expression of SLP65 isoforms in BCR-ABL1 pre–B ALL
cells. SLP65 cDNA fragments were amplified from normal human
CD19 CD34 Ig	 pro-B, CD10 CD19 Iglow pre–B, CD10	
CD19 CD27 Ighigh memory B cells (C), and BCR-ABL1 ALL cells,
including a BCR-ABL1 cell line in the presence or absence of STI571
(A) and enriched ALL cells from seven leukemia patients (Table I, cases
XIII–XIX) before and after treatment with STI571 (B). cDNA amounts
were normalized using GAPDH as a standard (A–C). The primers used
amplified full-length SLP65 and an isoform encoding truncated SLP65
(SLP65 C). For leukemia cases XIII, XIV, XVI, XVII, and XIX described
in B, FACS® data on coexpression of CD10 and/or CD34 on leukemic
CD19 cells was available before and after STI571 treatment. a, Percentage of
CD19 leukemia cells coexpressing CD10 or CD34.
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pre–B cell receptor; B cell precursors in a patient carrying a
deleterious mutation of the SLP65 gene are arrested at the
pro–B cell stage of development (29). In mice, SLP65 defi-
ciency does not prevent expression of a pre–B cell recep-
tor, but results in a partial differentiation block at the pre–B
cell stage (7). Of note, in 50% of childhood pre–B ALL
cases, SLP65 expression is defective, which results in com-
promised pre–B cell receptor signaling (8). In these cases,
either no SLP65 was expressed or an aberrant splice variant
including one or two additional exons was inserted be-
tween SLP65 exons III and IV (8). Inclusion of additional
exons, termed IIIa and IIIb introduced a premature transla-
tion stop resulting in loss of the COOH terminus of SLP65
(SLP65 C). The COOH terminus of SLP65 encompasses
tyrosine 96, whose phosphorylation is critical for SLP65 ac-
tivity in mice (8). Therefore, we tested whether SLP65 ex-
pression is deranged in BCR-ABL1 pre–B ALL cells and
whether SLP65 deficiency is linked to the BCR-ABL1 ki-
nase activity. To this end, we analyzed SLP65 isoform ex-
pression in primary pre–B cells from the bone marrow of
four healthy donors and STI571-treated and untreated
BCR-ABL1 pre–B ALL cells (Fig. 6 A). Although normal
pre–B cells expressed high levels of the canonical SLP65
isoform and only very little alternatively spliced SLP65
C, this pattern was almost inverted in BCR-ABL1
pre–B ALL cells. Also, when BCR-ABL1 pre–B ALL
cells were incubated in the presence of STI571 for 48 h,
the leukemia cells expressed the SLP65 C transcript, al-
though at lower levels. Given that short-term treatment
with STI571 partially restored (pre–B cell receptor respon-
siveness; Fig. 5 C) and induced selection for differentiating
leukemia cells expressing high levels of Ig  heavy chains
(Fig. 3), we sorted Ig  leukemia cells. STI571-treated
leukemia cells, which have recovered pre–B cell receptor
expression, also regained normal SLP65 expression (Fig. 6
A) in parallel with restored pre–B cell receptor responsive-
ness (Fig. 5 C). In humans, deleterious mutation of the
SLP65 gene prevents expression and function of the pre–B
cell receptor on mutant B cell precursors (29). However,
inactivating mutations within pre–B cell receptor–related
genes (including IGHC, Ig, Ig, VpreB, and 5) do not
interfere with SLP65 expression (29). Therefore, deranged
SLP65 expression is likely the cause rather than the conse-
quence of compromised pre–B cell receptor signaling in
BCR-ABL1 pre–B ALL cells.
To determine whether deranged SLP65 expression is
linked to BCR-ABL1 kinase activity also in primary BCR-
ABL1 pre–B ALL leukemia cells, we analyzed the pattern
of SLP65 isoform expression in enriched leukemia cells
from seven patients before and after treatment with
STI571. Comparing matched pairs of leukemia samples, we
identified three patients in which the leukemia cells ex-
pressed SLP65 only at low levels, if at all (cases XVI, XVII,
and XIX; Fig. 6 B). In these cases, treatment by STI571
had no effect on SLP65 isoform expression. Given that the
leukemia samples had a purity of 80 percent, weak
SLP65 expression in these cases can be attributed to few
contaminating normal bystander B cells. In four cases, ex-
pression of the canonical SLP65 isoform encoding the full-
length protein was accompanied by the expression of
SLP65 C. Treatment with STI571 not only increased
mRNA levels of full-length SLP65 but also abolished ex-
pression of the truncated splice variant (Fig. 6 B).
Given that STI571 treatment of the BCR-ABL1 ALL
cell lines BV173, NALM1, and SUP-B15 resulted in the
preferential outgrowth of more differentiated subclones
(Figs. 2 and 4), which further differentiate into Ig high
light chain–expressing immature B cells (Fig. 4), we won-
dered whether also in patients the BCR-ABL1 leukemia
cells surviving STI571 treatment tend to exhibit a more
mature phenotype. Therefore, we analyzed primary B lym-
phoid bone marrow cells from seven leukemia patients be-
fore and after STI571 treatment by flow cytometry and cal-
culated the percentage of CD19 cells, which coexpress
CD34 and/or CD10. In the human, CD19 CD34 cells
are considered pro–B cells and CD19 CD10 CD34	
cells include pre–B cells and immature B cells, whereas ma-
ture B cell subsets in human bone marrow and the periph-
eral blood typically express CD19 but neither CD10 nor
CD34 (12). Based on this rough classification, from 46 to
98% of untreated BCR-ABL1 leukemia cells coexpress
CD34 and, thus, exhibit a pro–B cell–like phenotype (Fig.
6 B). After STI571 treatment, the percentage of cells dis-
playing a pro–B cell–like phenotype remains high in three
cases (XVI, XVII, and XIX). However, in two other cases,
the fraction of pro–B cell–like leukemia cells drops to 2 and
8% (cases XIII and XIV; Fig. 6 B, bottom). The remaining
cells show a more mature phenotype resembling pre–B or
immature B cells. Of note, STI571-induced conversion of
primary leukemia cases from a pro–B cell–like to a pre–B
cell–/immature B cell–like phenotype correlates with ther-
apy-related correction of SLP65 isoform expression in
these cases (Fig. 6 B). Three cases in which STI571 treat-
ment had no effect on SLP65 mRNA expression also did
not convert to a more differentiated phenotype in response
to STI571 therapy (cases XVI, XVII, and XIX; Fig. 6 B).
From two cases, no flow cytometry data was available.
SLP65 C is nonfunctional, and by competing with
full-length SLP65 for binding to upstream kinases (e.g.,
SYK), it may have an inhibitory effect on signal transduc-
tion initiated from the pre–B cell receptor in pre–B ALL
cells. Although the negative regulatory effect of truncated
SLP65 is not fully elucidated, our results indicate that its
expression is linked to BCR-ABL1 kinase activity.
A Potential Link between SLP65 Deficiency, Secondary VH
Gene Rearrangement, and Loss of Coding Capacity for a 
Heavy Chain in BCR-ABL1 pre–B ALL Cells. SLP65
also functions as a sensor for the expression of a productive
VH region gene within a pre–B cell receptor complex and
halts the recombination machinery to prevent further, po-
tentially inactivating, rearrangement of IGH gene segments
(1). In the absence of functional SLP65, the recombination
machinery remains active and generates secondary VH re-
gion gene rearrangements even if V, D, and J segments have
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been productively rearranged (9). Assuming that SLP65 de-
ficiency is a common feature of BCR-ABL1 ALL, one
would predict that in most if not all cases, the leukemia
clone has undergone one or more rounds of secondary VH
gene rearrangement. Such secondary rearrangements can oc-
cur by replacement of an already rearranged VH gene seg-
ment by another (in most cases upstream) VH gene segment
(22). VH gene replacement typically uses a cRSS, which is
present in the 3 part of 40 out of 44 functional VH gene
segments (22). A hallmark for VH gene replacement are short
sequences (5–7 bp) within the VH-DH junction that are for-
eign to the actually rearranged VH gene segment but are
matching exactly the 3 end adjacent to the cRSS of another
previously rearranged VH gene. It is very unlikely that 5–7
bp stretches matching the extreme 3 part of another VH
gene within the VH-DH joint can be randomly generated as
a by-product of junctional diversification (P  0.009; refer-
ence 22). Therefore, these short sequences are considered
vestiges of a previously rearranged VH gene segment. Ana-
lyzing the IGH VDJ rearrangements for footprints of sec-
ondary rearrangements, we found indication of VH gene re-
placement in 9 out of 12 leukemia cases (Table III). In eight
out of nine cases, the potential secondary rearrangement uses
a donor VH segment located upstream from the initially re-
arranged (recipient) VH gene segment (Table III). One
potential VH replacement might reflect an inversion or trans-
recombination event as described previously (22). A com-
prehensive analysis of IGH VDJ rearrangements amplified
from normal human immature B cells identified traces of VH
gene replacement in 16 out of 343 sequences (5%; reference
22). Hence, the frequency of VH gene replacement in BCR-
ABL1 ALL cases is, at 75%, surprisingly high.
Therefore, defective SLP65 expression (Fig. 6) is associ-
ated with and potentially the reason for secondary, mostly
nonproductive, VH gene rearrangements in 9 out of the 12
leukemia cases we analyzed (Table II). In agreement with a
pre–B cell origin of BCR-ABL1 ALL, one might envision
that the precursor of the leukemia clone underwent malig-
nant transformation after having passed the pre–B cell re-
ceptor checkpoint but subsequently lost coding capacity of
an initially productive Ig VH region gene by a deleterious
secondary VH gene rearrangement.
Assuming that BCR-ABL1 can relieve the selection pres-
sure for survival signals through the pre–B cell receptor,
next we tested whether truncated SLP65 is also expressed in
normal pro–B cells, in which selection for the expression of
a functional pre–B cell receptor is not operative. Although
CD19 Ig  chain	 VpreB	 pro–B cells express full-length
SLP65 at similar levels as in CD19 Ig  chain Vpre-B
pre–B cells and CD19 CD27 MBC cells, SLP65 C is
only expressed in pro–B cells (Fig. 6 C). As SLP65 isoform
expression is similar in BCR-ABL1 pre–B ALL and nor-
mal human CD19 Ig 	 VpreB	 pro–B cells, we con-
clude that SLP65 C is not a marker for B lineage leukemia
cells, but rather for B lymphoid cells that are not selected for
the expression of an active pre–B cell receptor.
Perspective. A broad range of pre–B cell receptor–
related signaling molecules and transcription factors is
transcriptionally silenced in BCR-ABL1 pre–B ALL as
compared with human pre–B cells. Loss of pre–B cell re-
ceptor–related molecules as observed by SAGE (Figs. 1 and
2) may reflect that the BCR-ABL1 kinase may have re-
lieved the selection pressure for the expression of these
molecules. In the presence of autonomous BCR-ABL1 ki-
Table III. Indication of Potential VH Gene Replacement in VH Region Genes of BCR-ABL1 Pre–B ALL Clones
Case 3 part of recipient VH 3 part of donor VH VH-DH DH
I VH1.8 CGTGTATTACTGTGCGAGAGG VH4.34 GTGTATTACTGTGCG AGAGGGGGGTA GGGAATAGCA DH6.13-JH5
II VH1.58 CGTGTATTACTGTGCGGCAGA VH4.61 GTGTATTACTGTGCGAGAGA CACGGCAGATG TATTGTAGTAGTACCCCC DH2.2-JH4
V VH2.5 CACATATTACTGTGCACACAGACC VH5.51 ATGTATTACTGTGCG AGACACACAGT GAGAGAAACCAGCC DH1.26-JH1
VI VH1.2a CGTGTATTACTGTGCGAGAGA VH3.30 GTGTATTACTGTGCG CGAGAGATCCCCCTTC TATTACTATGA DH3.22-JH3
VII VH2.5 CACATATTACTGTGCACACAGACC VH1.46 GTGTATTACTGTGCGAG AGACCGCT GGGTATAGCAGCAGCTG DH6.13-JH4
VIII VH2.70b CACATATTACTGTGCACACAGAC VH2.5 ACATATTACTGTGCA CACAGCCCCGGGATCCC CGGGATAGTAGTG DH3.22-JH4
IX VH1.24 CGTGTATTACTGTGCAACAGA VH1.46 GTGTATTACTGTGCGAGA CCAACAG ACCGTGGTTCGGGGA DH3.10-JH5
X VH3.38 CGTGTATTACTGTGCCAGATATAc VH3.53 GTGTATTACTGTGCGAGA GTTGCCAGGGGG TGGTGTATGCTATACC DH2.8-JH6
XI VH3.38 CGTGTATTACTGTGCCAGATATA VH3.48 GTGTATTACTGTGGCGA GCCAGATATTGT AGTGGTGGTAGCT DH2.15-JH3
cRSS motifs (bold). Footprints of recipient VH gene segments (underline).
aThe footprint of this potential VH replacement may be also derived from VH1.3, VH1.18, VH3.7, VH3.11, VH3.20, VH3.21, and VH4.4 gene segments.
bLikely generated by inversion or transrecombination events.
cThe footprint of VH replacement in this case also involves the last two nucleotides of the cRSS motif.
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nase activity, pre–B ALL cells become nonresponsive to
pre–B cell receptor engagement (Fig. 5). As a consequence,
molecules needed for transduction of survival signals through
the pre–B cell receptor, disappear from the gene expression
program of the leukemic cells (Fig. 1, SAGE). Conversely,
inhibition of BCR-ABL1 reconstitutes dependence on sur-
vival signals initiated from surface receptors, including the
pre–B cell receptor (Fig. 3). It is even conceivable that de-
fault signaling through the pre–B cell receptor represents a
mechanism to acquire drug resistance that is available to
BCR-ABL1 pre–B ALL cells but not to other malignant
cells carrying a BCR-ABL1 gene rearrangement (e.g.,
chronic myeloid leukemia [CML] cells). In this regard, it is
interesting to note that treatment failure of STI571 is fre-
quent in pre–B ALL but not in CMLs harboring a BCR-
ABL1 fusion gene (30). Moreover, STI571 resistant as op-
posed to STI571-sensitive BCR-ABL1 pre–B ALL cells
exhibit high expression levels of Bruton’s tyrosine kinase,
which represents a critical component of pre–B cell recep-
tor signal transduction cascade (15). Therefore, resumption
of pre–B cell receptor signaling may represent a mechanism
to escape immediate apoptosis induced by STI571 and
open a time frame during which secondary transforming
events that confer permanent STI571 resistance (e.g., mu-
tations within the ATP-binding site of the ABL1 kinase
domain) can occur.
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